(₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
---|---|---|---|---|---|
Total Income | 482.94 | 548.55 | 482.87 | -12.0% | 0.0% |
Total Expenses | 431.77 | 458.55 | 385.32 | -5.8% | 12.1% |
Profit Before Tax | 51.18 | 90.00 | 97.55 | -43.1% | -47.5% |
Tax | 14.14 | 17.96 | 18.37 | -21.3% | -23.0% |
Profit After Tax | 37.04 | 72.04 | 79.17 | -48.6% | -53.2% |
Earnings Per Share | 2.30 | 4.40 | 4.90 | -47.7% | -53.1% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
FDC Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the development, manufacturing, and marketing of a wide range of healthcare products. Its product portfolio includes prescription drugs, over-the-counter medications, and nutraceuticals. The company has established a significant presence in both domestic and international markets. While specific recent developments for FDC Ltd are not provided in the data, the company typically focuses on innovation and expanding its product offerings to meet the evolving healthcare needs.
For the third quarter of the fiscal year 2025 (Q3FY25), FDC Ltd reported total income of ₹482.94 crores. This marks a decrease of 12.0% from the previous quarter (Q2FY25), where the total income was ₹548.55 crores. When compared to the same quarter in the previous year (Q3FY24), the total income remained stable, showing no percentage change, as it was ₹482.87 crores then. This indicates a consistent year-over-year performance in terms of revenue generation.
In terms of profitability, FDC Ltd experienced a notable decline in the third quarter of FY25. The profit before tax for Q3FY25 was ₹51.18 crores, which represents a decrease of 43.1% from the preceding quarter's figure of ₹90.00 crores. Year-over-year, there was a 47.5% reduction from Q3FY24's profit before tax of ₹97.55 crores. The profit after tax also declined significantly to ₹37.04 crores in Q3FY25, down 48.6% from ₹72.04 crores in Q2FY25 and 53.2% from ₹79.17 crores in Q3FY24, demonstrating substantial changes in profitability metrics.
The total expenses for FDC Ltd in Q3FY25 were ₹431.77 crores, showing a decrease of 5.8% from ₹458.55 crores in Q2FY25. However, compared to Q3FY24, there was an increase of 12.1% from ₹385.32 crores. This indicates a rise in operational spending on a year-over-year basis. The tax expense for Q3FY25 was ₹14.14 crores, down 21.3% from Q2FY25's ₹17.96 crores and 23.0% from Q3FY24's ₹18.37 crores. The earnings per share (EPS) also saw a decline to ₹2.30 in Q3FY25 from ₹4.40 in Q2FY25 and ₹4.90 in Q3FY24, reflecting the changes in profitability and overall financial health of the company.